We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Home » Targacept Begins Phase II Studies of TC-6987 in Asthma and Type 2 Diabetes
Targacept Begins Phase II Studies of TC-6987 in Asthma and Type 2 Diabetes
February 9, 2011
Targacept, Inc. Wednesday announced the initiation of separate Phase II clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes. StreetInsider
